A Prolia lawsuit today means an individual product liability case against Amgen, typically brought by a patient alleging a serious bone or calcium-related injury from the osteoporosis injection denosumab. As of 2026, no class action has been certified and no multidistrict litigation exists for Prolia personal injury claims. The only Prolia MDL on the federal docket is a patent dispute between Amgen and biosimilar makers, which does not involve patient injuries.
Where Prolia Injury Lawsuits Stand
Individual suits have been filed in state and federal courts, but they are not consolidated. There is no publicly available record of a certified class action tied to Prolia injuries, and at least one law firm that once solicited these cases, The Schmidt Firm, has publicly stated it is no longer accepting them.1The Schmidt Firm. No FDA Warnings for Prolia Femur Fractures
The most instructive documented case is Brooks v. Amgen, Inc., filed in the U.S. District Court for the Middle District of Louisiana. Sheila Brooks alleged she developed jaw necrosis after a Prolia injection in May 2017 and sued under the Louisiana Products Liability Act for inadequate warning, defective design, and manufacturing defect. In February 2019, the court dismissed the inadequate-warning claim without prejudice under the learned intermediary doctrine, which holds that a drug manufacturer’s duty to warn runs to the prescribing physician rather than the patient. The manufacturing defect claim was also dismissed for lack of specificity: Brooks had not alleged that the particular unit of Prolia she received deviated from Amgen’s specifications.2CaseMine. Brooks v. Amgen Inc.
Two practical points fall out of that ruling for anyone considering a claim. First, the failure-to-warn theory usually depends on what the prescribing doctor was told, not what the patient read. Second, a manufacturing defect claim needs allegations tied to the specific dose the patient received, not general concerns about the drug.
The Injuries Driving These Claims
Three categories of harm dominate reports and litigation around Prolia: severe hypocalcemia in kidney patients, rebound vertebral fractures after stopping the drug, and osteonecrosis of the jaw. Each now appears in the drug’s FDA-approved labeling, which shapes what a plaintiff can plausibly allege and when.
Severe Hypocalcemia and the 2024 Boxed Warning
On January 19, 2024, the FDA added a Boxed Warning, its most prominent safety alert, to Prolia’s prescribing information for severe hypocalcemia in patients with advanced chronic kidney disease.3FDA. FDA Adds Boxed Warning Increased Risk Severe Hypocalcemia Patients Advanced Chronic Kidney Disease The action followed a November 2022 safety communication and two FDA Medicare studies. One found that 41.1% of dialysis-dependent women treated with Prolia developed severe hypocalcemia within 12 weeks, compared with 2% of those on oral bisphosphonates. The greatest risk window was two to ten weeks after injection, and complications included seizures, cardiac arrhythmias, and death.4FDA. Prolia Denosumab Drug Safety Communication – FDA Adds Boxed Warning
The updated labeling now directs providers to assess kidney function before prescribing, correct any calcium deficiency, provide calcium and activated vitamin D supplementation, and monitor blood calcium weekly for the first month and monthly afterward.5FDA. Prolia Prescribing Information 2024 Amgen also updated the drug’s Risk Evaluation and Mitigation Strategy (REMS) to require that each patient receive a guide covering hypocalcemia risks and symptoms.6Prolia HCP. Prolia REMS Letter for Healthcare Providers
Rebound Vertebral Fractures After Discontinuation
Prolia’s label carries a separate warning about multiple vertebral fractures after discontinuation. Because the drug’s suppression of bone turnover is highly reversible, stopping it can produce a “hyperresorptive state” where bone breakdown surges past pre-treatment levels.7Cleveland Clinic ConsultQD. Rapid Bone Loss and Multiple Vertebral Fractures After Denosumab Cessation The prescribing information notes that new vertebral fractures have appeared as early as seven months after the last dose and that bone mineral density can return to pre-treatment levels within 18 months of stopping.8FDA. Prolia Prescribing Information 2022
A post-hoc analysis of the pivotal FREEDOM trial found the vertebral fracture rate climbed from 1.2 per 100 participant-years on Prolia to 7.1 per 100 participant-years after stopping. Among those who fractured, roughly 61% had two or more, and about 23% had four or more.9PubMed Central. Rebound Vertebral Fractures After Denosumab Discontinuation The label now states that patients should be transitioned to an alternative bone-preserving therapy when Prolia is stopped.
Osteonecrosis of the Jaw and Atypical Femur Fractures
Osteonecrosis of the jaw, in which the jawbone weakens and breaks down, is a rare but recognized risk, particularly in patients with poor dental health or those undergoing jaw procedures. Atypical femoral fractures are also listed as a rare risk associated with long-term use.10UK Government. Denosumab 60mg Prolia Increased Risk of Multiple Vertebral Fractures A large analysis of the FDA’s adverse event reporting database from 2010 through 2023 identified osteonecrosis of the jaw as one of the strongest safety signals for the drug, with a reporting odds ratio of nearly 75 compared with other medications in the database. The same analysis counted more than 130,000 denosumab-related adverse event reports, about 48% classified as serious and roughly 13% involving a fatality, though FAERS tracks reports rather than confirmed causal relationships.11Frontiers in Pharmacology. Denosumab Adverse Drug Reactions FAERS Analysis
The New Jersey MDL Is Not About Patient Injuries
Anyone searching for a Prolia MDL will find one, but it is a patent case. In re Denosumab Patent Litigation, MDL No. 3138, is pending in the U.S. District Court for the District of New Jersey before Judge Christine P. O’Hearn, and it involves Amgen’s infringement claims against biosimilar manufacturers under the Biologics Price Competition and Innovation Act.12GovInfo. In Re Denosumab Patent Litigation MDL No. 3138 It does not include product liability claims, and joining it is not a path for an injured patient.
What This Means for a Potential Claim
The regulatory picture has shifted the ground under Prolia claims. The 2024 Boxed Warning and updated REMS mean that the risks of severe hypocalcemia in advanced kidney disease are now explicitly disclosed to prescribers and patients, which strengthens Amgen’s learned-intermediary defense for injections given after the label change. Rebound vertebral fractures and osteonecrosis of the jaw have carried warnings for longer, so a failure-to-warn claim on those risks will turn on what the label said at the time of injection and what the prescribing doctor was told.
Injury cases remain possible, but they run one plaintiff at a time. If you believe you were harmed by Prolia, the file supports these baseline steps: preserve the injection records and the dates of each dose, obtain the prescribing information in effect on those dates, document the injury and treatment, and consult a product liability attorney who can evaluate the claim under your state’s law. Do not stop Prolia on your own; the label warns that discontinuation without a follow-on therapy carries its own fracture risk.